NCT06107517 Reducing Delirium After CABG Surgery With Early Activation and Sleep-Promoting Routines
| NCT ID | NCT06107517 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National University Hospital, Singapore |
| Condition | Delirium, Postoperative |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-01-08 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-01-08 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized-controlled trial (RCT) is to compare the effectiveness of the DREAMS-OT intervention with standard care in reducing post-Coronary Artery Bypass Graft (CABG) surgery delirium in patients undergoing CABG surgery. The aims of the study are: 1. To determine if early and intensive OT will lower the incidence of post-op delirium in CABG patients compared to standard are. 2. To determine the cost effectiveness of the DREAMS-OT intervention. The study team will compare intervention group and standard care group (control group) to see if there is a reduction in the incidence of delirium in patients 5 days post-CABG.
Eligibility Criteria
Inclusion Criteria: * Patients deemed medically suitable for elective CABG surgery * Patients aged 21 years and above * Patients who are English or Mandarin speaking. * Patients who are able to provide consent Exclusion Criteria: * Patients who speak other languages are excluded due to the language requirements of certain outcome measures. * Patients with premorbid severe hearing impairment, severe cognitive impairment, progressive neurological disorders and psychological disorders will be excluded. * Patients with surgical complications resulting in profuse bleeding from any invasive sites, septic shock unresponsive to maximal treatment, and those who are moribund or have an expected mortality within 48 hours will be excluded. * Pregnant women will also be excluded from the study as well. * Patients who develop delirium before initiation of the treatment are also excluded from the study.
Contact & Investigator
Su Ren Wong
PRINCIPAL INVESTIGATOR
National University Hospital, Singapore
Frequently Asked Questions
Who can join the NCT06107517 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 99 Years, studying Delirium, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06107517 currently recruiting?
Yes, NCT06107517 is actively recruiting participants. Contact the research team at megan_huei_lin_tan@nuhs.edu.sg for enrollment information.
Where is the NCT06107517 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT06107517 clinical trial?
NCT06107517 is sponsored by National University Hospital, Singapore. The principal investigator is Su Ren Wong at National University Hospital, Singapore. The trial plans to enroll 300 participants.